Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr. habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. From 1999 to 2017 he led the Tübingen Ageing and Tumour Immunology (TATI) group within the Second Department of Internal Medicine, University of Tübingen Hospitals System. He remains affiliated part-time with the department at the Center for Medical Research, University of Tübingen. He is currently affiliated with the Cancer Solutions Program, Health Sciences North Research Institute of Canada, Sudbury, ON, and is a Visiting Professor at Nottingham Trent University, UK, King´s College London, London, UK, and is an Honorary Professor at Manchester University, UK.
He is Co-Editor-in Chief of Cancer Immunology Immunotherapy, and is Deputy or Associate Editor in several other journals. He has authored or co-authored 270 peer-reviewed original articles from a total of 486 PubMed-listed publications, has edited 3 books and co-edited several others (as of December 2018 in Google Scholar, 24,006 citations, H-index 87). He has coordinated three European Union collaborative programs on immunosenescence (EUCAMBIS, ImAginE and T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was a member of the Sanofi-Pasteur-MSD and Sanofi-Aventis Advisory Boards on Immunosenescence and Vaccination, and of the WHO Initiative for Vaccine Research Advisory Board on the Impact of Ageing on Vaccination.
His research interests remain centered on vaccination, cancer immunology and immunotherapy, and immunogerontology.